These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 16464564

  • 1. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
    Peggs KS, Quezada SA, Korman AJ, Allison JP.
    Curr Opin Immunol; 2006 Apr; 18(2):206-13. PubMed ID: 16464564
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
    Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J.
    J Clin Oncol; 2005 Dec 10; 23(35):8968-77. PubMed ID: 16204013
    [Abstract] [Full Text] [Related]

  • 3. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
    Korman A, Yellin M, Keler T.
    Curr Opin Investig Drugs; 2005 Jun 10; 6(6):582-91. PubMed ID: 15988909
    [Abstract] [Full Text] [Related]

  • 4. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS, Quezada SA, Allison JP.
    Immunol Rev; 2008 Aug 10; 224():141-65. PubMed ID: 18759925
    [Abstract] [Full Text] [Related]

  • 5. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D, Fong L.
    J Clin Oncol; 2005 Dec 10; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immune modulation in melanoma and advanced cancer therapy: anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibodies.
    Esper P.
    Clin J Oncol Nurs; 2009 Oct 10; 13(5):547-54. PubMed ID: 19793711
    [Abstract] [Full Text] [Related]

  • 9. [Telomerase, a universal target in immunotherapy strategies against tumor?].
    Rousseau R, Soria JC.
    Bull Cancer; 2000 Dec 10; 87(12):895-901. PubMed ID: 11174119
    [Abstract] [Full Text] [Related]

  • 10. Future directions in tumor immunotherapy: CTLA4 blockade.
    Gulley JL, Dahut WL.
    Nat Clin Pract Oncol; 2007 Mar 10; 4(3):136-7. PubMed ID: 17327854
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors.
    Agarwala SS, Ribas A.
    J Immunother; 2010 Mar 10; 33(6):557-69. PubMed ID: 20551840
    [Abstract] [Full Text] [Related]

  • 15. Possible applications of antibodies or their genes in cancer therapy.
    Kuroki M, Huang J, Shibaguchi H, Tanaka T, Zhao J, Luo N, Hachimine K, Kinugasa T, Maekawa S, Enatsu S, Hamanaka W, Fukami T, Kuroki M.
    Anticancer Res; 2006 Mar 10; 26(6A):4019-25. PubMed ID: 17195452
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.